The UK's Medical Research Council has issued a GBP2.0-million ($3.3 million) call for proposals in methodology research in collaboration with the National Institute for Health and Clinical Excellence (NICE), which recommends medical treatment under the National Health Service excluding Scotland.
The need for methodological research to underpin decision-making by the NICE was highlighted in a House of Commons Health Select Committee Report in 2008. Since then, the MRC has been working with NICE to identify its methodological research priorities and the new call for proposals has been developed in response to the requirements identified. Commenting on the announcement, Peter Littlejohns, NICE Clinical and Public Health Director, said: "NICE is tasked with making some of the most difficult decisions in public life, decisions that have an impact on the millions of people who use the NHS. It's therefore vital for people to continue to have confidence not just in the guidance we produce, but also in the processes and methods we use to produce it."
Prof Littlejohns continued by noting that "this research will address some of the key issues in our process and methodology. Of particular importance are the issues around how we measure health-related quality of life. This is translational research, it's about getting things into our process and methodology that will make a real difference to patients."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze